Welcome to our dedicated page for Inspira Technologies Oxy B.H.N. Ltd. Warrant news (Ticker: IINNW), a resource for investors and traders seeking the latest updates and insights on Inspira Technologies Oxy B.H.N. Ltd. Warrant stock.
Inspira Technologies Oxy BHN Ltd is a specialty medical device company focused on developing innovative respiratory support technology as an alternative to mechanical ventilation. By 2020, over 600,000 patients in the U.S. will need mechanical ventilation, with a significant portion requiring ICU admission, costing an estimated $64 billion annually. The company's OxyLink technology, an advanced nano vesicle device, introduces an intravascular oxygenation system to enhance blood oxygen levels and reduce carbon dioxide, enabling physicians to address primary ventilatory conditions effectively.
The company has recently received 510(k) class II clearance from the U.S. FDA for its INSPIRA ART100 Cardiopulmonary Bypass System. Inspira Technologies aims to revolutionize the respiratory care market with its innovative products, including the INSPIRA ART (Gen 2) system designed to elevate patient oxygen levels and potentially reduce the need for mechanical ventilation, providing new treatment alternatives and enhancing patient care.
Rhea-AI Summary
Inspira Technologies OXY BHN Ltd. (Nasdaq: IINN) has announced a non-binding Letter of Intent (LOI) with Shamir Medical Center to assess the integration and performance of the INSPIRA™ ART100 device within the hospital's clinical environment. The LOI solidifies the mutual commitment of both parties to evaluate the device's fit, efficiency, and overall impact on healthcare delivery. The collaboration aims to enhance life-support care and establish a pathway for adoption in local and international markets.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.03%
Tags
-
Rhea-AI Summary
Inspira Technologies OXY B.H.N Ltd. (Nasdaq: IINN) has announced a summary distribution agreement with Glo-Med Networks, Inc. to potentially provide $32.6 million over a 5-year period. The agreement designates Glo-Med as the exclusive distributor in Saudi Arabia, United Arab Emirates, and Bahrain for the INSPIRA™ ART devices. The agreement is subject to regulatory approvals and is seen as a significant step for both companies in broadening their range of innovative products in the healthcare market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.87%
Tags
-
Rhea-AI Summary
Inspira Technologies OXY B.H.N Ltd. (Nasdaq: IINN) announces the development of a single-use disposable blood oxygenation kit for its INSPIRA ART medical device series, targeting FDA authorization in 2025. The kit is designed to be compatible with various life support machines, potentially reducing hospital costs. CEO Dagi Ben-Noon anticipates revenue streams based on the disposable razorblade business model, along with the FDA clearance of the INSPIRA™ ART100 device in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.24%
Tags
Rhea-AI Summary
Inspira Technologies OXY B.H.N Ltd. (Nasdaq: IINN) has signed a non-binding Letter of Intent with Northwestern Memorial Hospital, a top-ranked hospital in the United States, to explore collaboration for the evaluation of its INSPIRA ART100 device. The agreement is subject to FDA clearance and entering a definitive evaluation agreement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.77%
Tags
-
Rhea-AI Summary
Inspira Technologies OXY BHN Ltd. (Nasdaq: IINN) has closed a registered direct offering of 3,031,250 ordinary shares at a purchase price of $1.28 per share, with aggregate gross proceeds of approximately $3.88 million. The company also issued warrants to purchase up to an aggregate of 3,031,250 ordinary shares at an exercise price of $1.28 per share. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.75%
Tags
-
Rhea-AI Summary
Inspira Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) (NASDAQ: IINNW) has entered into a definitive agreement for the issuance and sale of 3,031,250 ordinary shares at a purchase price of $1.28 per share in a registered direct offering. The company will also issue unregistered warrants to purchase up to an aggregate of 3,031,250 ordinary shares at an exercise price of $1.28 per share.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.72%
Tags
Rhea-AI Summary
Inspira Technologies OXY BHN Ltd. (NASDAQ: IINN) Announces Breakthrough in Sensor Technology for Real-Time Blood Monitoring
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.72%
Tags
-
Rhea-AI Summary
Inspira Technologies OXY BHN Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) is set to attend the 42nd Annual J.P. Morgan Healthcare Conference in January 2024. The Company's CEO and President will meet with medical device and strategic consulting companies, aiming to advance their groundbreaking life support technology. The expected FDA clearance for their innovative life support device that directly oxygenates blood is a significant milestone on the horizon.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9%
Tags
-
Rhea-AI Summary
Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) is pleased to announce the appointment of Dr. Dan Gorfil to its medical advisory board. Dr. Gorfil, a distinguished specialist in cardiac surgery and intensive care medicine, is expected to significantly contribute to the deployment of the INSPIRA™ ART100. U.S. Food and Drug Administration (FDA) approval is expected in the first half of 2024. The company is leading the way in transforming life-support care, with innovative solutions that pave the way for direct blood oxygenation and AI-driven monitoring systems, potentially enhancing patient outcomes and streamlining hospital operations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.9%
Tags
Rhea-AI Summary
Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) announces partnership with Ennocure MedTech Ltd. to develop bio-electronic technology for bloodstream infection prevention. The company aims to revolutionize life support technology by integrating oxygenation and infection prevention solutions, potentially improving patient outcomes and reducing healthcare costs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.9%
Tags
FAQ
What is the current stock price of Inspira Technologies Oxy B.H.N. Ltd. Warrant (IINNW)?
The current stock price of Inspira Technologies Oxy B.H.N. Ltd. Warrant (IINNW) is $0.38 as of November 1, 2024.
What is Inspira Technologies Oxy BHN Ltd known for?
Inspira Technologies specializes in developing respiratory support technology as an alternative to mechanical ventilation.
What is the significance of OxyLink technology?
OxyLink is an advanced intravascular oxygenation apparatus that enhances blood oxygen levels and reduces carbon dioxide, facilitating effective treatment of ventilatory conditions.
What recent FDA clearance has Inspira Technologies received?
Inspira Technologies has received 510(k) class II clearance from the U.S. FDA for its INSPIRA ART100 Cardiopulmonary Bypass System.
How does the INSPIRA ART (Gen 2) system aim to revolutionize patient care?
The INSPIRA ART (Gen 2) system is designed to elevate patient oxygen levels, potentially reducing the need for mechanical ventilation and offering new treatment alternatives.
What is the core mission of Inspira Technologies?
Inspira Technologies aims to enhance patient care by developing innovative medical technologies that address critical respiratory needs and revolutionize the life support arena.
Inspira Technologies Oxy B.H.N. Ltd. Warrant